NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc's (NASDAQ: NTHI) NEO100 is testing a different answer to one of brain cancer’s oldest problems.
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


